|
|
|
|
|
|||||||
|
Session 36
Poster Session
Vpr 4:30-6:30 pm 4E-F |
to view the poster for an abstract.| 139-M. | Assessment of the Contributions of Vpr-Mediated G2/M Arrest and Nuclear Import to HIV-1 Replication in Culture P. V. Sanchez*1 and M. H. Malim2 1Univ. of Pennsylvania, Philadelphia and 2King's Coll., London, UK
| ||
| 140-M. | Cytoplasmic-Nuclear Shuffling of HIV-1 Vpr and Its Effect on Integrity of the Nuclear Envelope R. T. Elder1, M. Yu1, J. Hou1, M. Chen1, S. Priet2, A. Sheerer1, K. Chiu1, J. Sire2, and Y. Zhao*1 1Northwestern Univ. Med. Sch., Chicago, IL and 2INSERM, Marseille, France
| ||
| 141-M. | Involvement of HIV Vpr Protein in G2/M Arrest through Interaction with 14-3-3 M. Tsopanomichalou*1, T. Kino2, A. Gragerov1, G. Ilyina-Gragerova1, G. P. Chrousos2, and G. N. Pavlakis1 1NCI, NIH, Frederick, MD and 2NICHD, NIH, Bethesda, MD
| ||
| 142-M. | Multicopy Suppressors and Enhancers of Cell Cycle G2 Arrest Induced by HIV-1 Viral Protein R (Vpr) in Fission Yeast (Schizosaccharomyces Pombe) Z. Benko*, R. T. Elder, S. Innis, M. Yu, M. Chen, and Y. Zhao Northwestern Univ. Med. Sch., Chicago, IL
| ||
| 143-M. | Functional Significance of Naturally Occurring Mutants in HIV-1 Vpr P. K. Tungaturthi*1, S. P. Singh1, M. Cartas1, B. Tomkowicz1, V. Ayyavoo2, S. Mahalingam3, R. Murali4, and A. Srinivasan1 1Thomas Jefferson Univ., Philadelphia, PA; 2Univ. of Pittsburgh, PA; 3Ctr. for DNA Fingerprinting and Diagnostics, Hyderabad, India; and 4Univ. of Pennsylvania, Philadelphia
| ||
| 144-M. | Physical and Functional Interaction between Viral Protein R and p21WAFI B. E. Sawaya1, S. P. Singh*2, K. Khalili1, A. Clavo1, A. Srinivasan2, and S. Amini1 1Temple Univ. and 2Thomas Jefferson Univ., Philadelphia, PA
| ||
| 145-M. | HIV-1 Vpr Causes Cell Cycle Arrest via a Pathway Involving p38 MAP Kinase and ATR M. Roshal*, Y. Zhu, and V. Planelles Univ. of Rochester, NY
| ||
| 146-M. | Vpr Mutation R77Q Is Associated with Long-Term Non-Progressive HIV-Infection and an Impaired Ability to Induce T-Cell Depletion in Vivo J. Lum*1, O. J. Cohen2, D. H. Lynch4, A. A. Pilon1, J. E. Kim2, Z. Chen3, M. Montpetit3, J. Sanchez-Dardon1, N. Hawley-Foss1, G. Garber1, and A. D. Badley1 1Ottawa Hlth. Res. Inst., Ontario, Canada; 2NIAID, NIH, Bethesda, MD; 3Hlth. Ottawa, ON, Canada; and 4Immunex Corp., Seattle, WA
|
